159 related articles for article (PubMed ID: 24453033)
1. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.
Wang W; Guan S; Sun S; Jin Y; Lee KH; Chen Y; Wei J
Tumour Biol; 2014 May; 35(5):4901-5. PubMed ID: 24453033
[TBL] [Abstract][Full Text] [Related]
2. Investigation of circulating antibodies to ANXA1 in breast cancer.
Huang Y; Zhang C; Chen C; Sun S; Zheng H; Wan S; Meng Q; Chen Y; Wei J
Tumour Biol; 2015 Feb; 36(2):1233-6. PubMed ID: 25344217
[TBL] [Abstract][Full Text] [Related]
3. Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
Wang W; Zhong W; Chen C; Meng Q; Wei J
Anticancer Res; 2017 Jun; 37(6):3151-3155. PubMed ID: 28551657
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.
Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B
Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232
[TBL] [Abstract][Full Text] [Related]
5. Increased Levels of Circulating Anti-ANXA1 IgG Antibody in Patients with Non-Small Cell Lung Cancer.
Liang T; Han Z; Zhao H; Zhang X; Wang Y
Clin Lab; 2018 Jun; 64(6):895-900. PubMed ID: 29945332
[TBL] [Abstract][Full Text] [Related]
6. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
7. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
[TBL] [Abstract][Full Text] [Related]
8. Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer.
Liu S; Zhang X; Jiang Q; Liang T
FEBS Open Bio; 2020 Jul; 10(7):1288-1294. PubMed ID: 32392378
[TBL] [Abstract][Full Text] [Related]
9. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
[TBL] [Abstract][Full Text] [Related]
10. Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma.
Wang J; Xu Y; Zhao H; Zhang X
J Cancer Res Ther; 2017; 13(5):813-816. PubMed ID: 29237909
[TBL] [Abstract][Full Text] [Related]
11. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
12. A study of circulating anti-CD25 antibodies in non-small cell lung cancer.
Ye L; Li X; Sun S; Guan S; Wang M; Guan X; Lee KH; Wei J; Liu B
Clin Transl Oncol; 2013 Aug; 15(8):633-7. PubMed ID: 23263913
[TBL] [Abstract][Full Text] [Related]
13. Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma.
Akhtar J; Priya R; Jain V; Sakhuja P; Agarwal AK; Goyal S; Polisetty RV; Sirdeshmukh R; Kar S; Gautam P
BMC Cancer; 2020 Dec; 20(1):1175. PubMed ID: 33261560
[TBL] [Abstract][Full Text] [Related]
14. FOXP3 autoantibody as a potential early prognostic serum biomarker in patients with cervical cancer.
Xu S; Huangfu M; Jia X; Song X; Sun B; Lee KH; Liu L; Sun S
Int J Clin Oncol; 2015 Oct; 20(5):982-8. PubMed ID: 25681877
[TBL] [Abstract][Full Text] [Related]
15. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
16. Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer.
Wang T; Liu H; Pei L; Wang K; Song C; Wang P; Ye H; Zhang J; Ji Z; Ouyang S; Dai L
Clin Immunol; 2020 Jan; 210():108262. PubMed ID: 31629809
[TBL] [Abstract][Full Text] [Related]
17. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer.
Farlow EC; Patel K; Basu S; Lee BS; Kim AW; Coon JS; Faber LP; Bonomi P; Liptay MJ; Borgia JA
Clin Cancer Res; 2010 Jul; 16(13):3452-62. PubMed ID: 20570928
[TBL] [Abstract][Full Text] [Related]
18. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.
Brichory FM; Misek DE; Yim AM; Krause MC; Giordano TJ; Beer DG; Hanash SM
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9824-9. PubMed ID: 11504947
[TBL] [Abstract][Full Text] [Related]
19. A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer.
Liu Y; Liao Y; Xiang L; Jiang K; Li S; Huangfu M; Sun S
Int J Clin Oncol; 2017 Apr; 22(2):291-296. PubMed ID: 27778118
[TBL] [Abstract][Full Text] [Related]
20. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice.
Jett JR; Peek LJ; Fredericks L; Jewell W; Pingleton WW; Robertson JF
Lung Cancer; 2014 Jan; 83(1):51-5. PubMed ID: 24268382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]